<DOC>
	<DOCNO>NCT00464295</DOCNO>
	<brief_summary>In patient unresectable/advanced Hepatocellular Carcinoma receive Capecitabin , anticipate propose chemotherapy delay progression disease . It also expect proposed chemotherapy acceptable toxicity Quality life .</brief_summary>
	<brief_title>Phase II Trial Capecitabine Treatment Unresectable/ Metastatic Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>II . OBJECTIVES II.A . Primary Objectives : To evaluate response rate ( RR ) overall survival ( OS ) . II.B . Secondary Objective : To evaluate time progression ( TTP ) , median time response ( MTR ) , toxicity quality life ( QOL ) . III . STUDY DESIGN : III.A . Inclusion criterion : 1 . Written informed consent . 2 . Age 18 70 year . 3 . Documented least 2 three mention criterion evidence non-resectability . 1 . Radiological either CT Scan/US abdomen 2 . Biopsy , 3 . Serum alphafeto protein level 4 . Multi centric hepatoma TNM Classification Stage IV . 5 . Child 's class B C Child 's score maximum 11 . 6 . No active malignancy except localize basal squamous cell carcinoma skin carcinoma situ cervix . 7 . Life expectancy great 3 month . 8 . Current laboratory value must within limit list : Haemoglobin &gt; 8 g/dL WBC &gt; 4,000/uL Absolute Neutrophil Count &gt; 1,500/uL Platelets &gt; 75,000/uL 9 . ECOG Performance status &lt; 2 . 10 . Patients receive adjuvant neoadjuvant therapy eligible . A minimum interval 4 week since last chemotherapy require . 11 . Prior radiotherapy allow involve site use assess response 4 week elapse since completion radiotherapy . III.B . Exclusion criterion : 1 . History allergic reaction compound chemically related CAP . 2 . Concomitant previous malignancy within five year basal squamous cell carcinoma skin carcinoma situ cervix . 3 . Active , uncontrolled infection . . 5 . Concurrent medical problem could limit life expectancy ability patient receive chemotherapy . 6 . Mental condition could limit patient comprehend concept clinical trial complying requirement . 7 . Brain leptomeningeal involvement . 8 . Pre-existing neurotoxicity &gt; =grade 2 . 9 . Concomitant radiotherapy , unless localise bone pain control palliation . 10 . Being reproductive potential agree practice effective contraceptive method . 11 . Pregnancy lactation . 12 . Severe renal impairment Creatinine clearance &lt; 30ml/minute . 13 . Documented Cardiomyopathy severe coronary artery disease , history arrhythmia . IV . PATIENT REGISTRATION All patient enter study must register contacting : Drs . Kashif Anis/Zaigham Abbas -Research Co-ordinators The Aga Khan University Hospital , Dept Medicine/ Medical Oncology . Stadium Road , P.O . Box : 3500 , Karachi , 74800 , Pakistan Tel ( 021 ) 493-0051 V. THERAPY This Phase II trial study chemotherapy CAP non-resectable HCC . Prior chemotherapy , radiation therapy , surgery permit . Staging required CAT scan/Ultrasound abdomen bone scan necessary . Pre study evaluation include CBC , renal function assessment , liver function test . Patients require independent evaluation medical oncologist/gastroenterologist prior include study . Chemotherapy would give cycle 21 day . CAP would give oral tablet twice daily start day 1 day 14 . Medication standard anti-emetics , may include serotonin antagonist , may use administration chemotherapy . Duration chemotherapy administration would determine patient 's response . A patient progressive disease , able tolerate chemotherapy unacceptable toxicity would take study . Patients , response , continue chemotherapy till progression disease inability tolerate chemotherapy document . VI . DOSE MODIFICATION Hematologic Toxicity : Chemotherapy hold ANC &lt; 1,500/uL , and/or platelet count &lt; 50,000/uL . Treatment resume count recover . Growth factor use subsequent cycle delay secondary neutropenia . If recovery 3 week delay , patient take study . Renal dysfunction : Creatinine Clearance mL/min Dose &gt; 50 100 % 30-50 75 % &lt; 30 0 % ( treatment give ) Elevated Liver Function Tests : In event bilirubin elevate study , next cycle delay maximum 2 week . ( The follow dose modification dose capecitabine make AST and/or ALT and/or alkaline phosphatase level elevate : AST/ALT Alkaline Phosphatase Recommended dose ( % ) &gt; 1.5- &lt; 2.5 x normal &lt; 2.5 x normal 75 % &gt; 2.5- &lt; 5 x normal &gt; 2.5- &lt; 5 x normal 50 % &gt; 5 x normal &gt; 5 x normal Dose delay maximum 2 week . If recovery note ; patient go study . Cardio toxicity : Significant drop leave ventricular ejection fraction and/or clinical sign symptom cardiac failure result discontinuation study . Dose Modification : Dose reduction plan significant ( Grade III/IV ) hematologic non-hematologic toxicity observe . CAP shall reduce 25 % grade III/IV toxicity occur . Patient take study life threaten complication occurs . All grade III/IV toxicity record detail include date onset resolution/outcome . GI toxicity grade II include severe diarrhea , nausea , vomit stomatitis , dose modification do , hold 1 week along symptomatic treatment , improvement 2 week patient take study . VII . SERIOUS ADVERSE EVENT REPORTING All serious event ( define Appendix E protocol ) must report , soon aware : Drs . Kashif Anis/Zaigham Abbas , Aga Khan University Hospital VIII . EVALUATION Evaluation Treatment : Patient evaluation gastroenterology/oncology determine eligibility . All Patients : Diagnosis hepatoma help Biopsy possible , help CT Scan Serum alpha fetoprotein level , fulfil 2 3 criterion . Complete history physical examination . CBC , differential , platelet count , serum sodium , potassium , glucose , calcium , creatinine , bilirubin , alkaline phosphatase , AST , ALT , alpha fetoprotein ( AFP ) , prothrombin time PT Serum Albumin . CT scan abdomen contrast . Cardiac evaluation LVEF CT scan plain x-ray clinically indicate . Evaluation Chemotherapy : CBC , differential , platelet count , sodium , potassium , creatinine , glucose , bilirubin , alkaline phosphatase , AST/ALT . CBC repeat prior every chemotherapy course . Re-evaluation response every 3 course chemotherapy would do radio logically repeat CT scan/x ray indicate site disease involvement . Evaluation After chemotherapy : All patient follow thereafter cessation chemotherapy due progression disease , every three six month total five year evaluation five-year disease free overall survival . Evaluation toxicity profile . This base either NCIC common toxicity criterion ( attached end ) , major toxicity criterion ( e.g . NCI ) , document attached form .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written inform consent . Age 18 70 year . Documented least 2 three mention criterion evidence nonresectability . 1 . Radiological either CT Scan/US abdomen 2 . Biopsy , 3 . Serum alphafeto protein level Multi centric hepatoma TNM Classification Stage IV . Child 's class B C Child 's score maximum 11 . No active malignancy except localize basal squamous cell carcinoma skin carcinoma situ cervix . Life expectancy great 3 month . Current laboratory value must within limit list : Haemoglobin &gt; 8 g/dL WBC &gt; 4,000/uL Absolute Neutrophil Count &gt; 1,500/uL Platelets &gt; 75,000/uL ECOG Performance status &lt; 2 . Patients receive adjuvant neoadjuvant therapy eligible . A minimum interval 4 week since last chemotherapy require . Prior radiotherapy allow involve site use assess response 4 week elapse since completion radiotherapy . History allergic reaction compound chemically related CAP . Concomitant previous malignancy within five year basal squamous cell carcinoma skin carcinoma situ cervix . Active , uncontrolled infection . . Concurrent medical problem could limit life expectancy ability patient receive chemotherapy . Mental condition could limit patient comprehend concept clinical trial complying requirement . Brain leptomeningeal involvement . Preexisting neurotoxicity &gt; =grade 2 . Concomitant radiotherapy , unless localise bone pain control palliation . Being reproductive potential agree practice effective contraceptive method . Pregnancy lactation . Severe renal impairment Creatinine clearance &lt; 30ml/minute . Documented Cardiomyopathy severe coronary artery disease , history arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Phase 2 Trial</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Treatment Efficacy</keyword>
</DOC>